Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million



BEIJING and CLAREMONT, Calif., March 26 /Xinhua-PRNewswire-FirstCall/
-- Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT)
announced that revenues for the year ended December 31, 2007 were
$9,129,779 an increase of 264.2% over $2,506,715 for 2006.

Net sales from continuing operations were $9,129,779 and $2,506,715 for
the twelve months ended December 31, 2007 and 2006, respectively,
representing an increase of $6,623,064 or 264.2%. The significant increase
is mainly due to the notable expansion in Kiwa’s principal operations,
including its bio- fertilizer business and bio-enhanced feed business.

—During 2007, revenue generated from Kiwa’s bio-fertilizer business
increased from $46,926 to $241,357, representing a 414.3% increase. The
rapid increase reflects the impact of the marketing efforts that began
two years ago.
—Net sales of bio-enhanced feeds increased 261.3%, from $2,459,789 in
2006 to $8,888,422 in 2007.
The net loss from continuing operations for 2007 was $2,893,359
(including non-cash expenses $1,408,239) compared to and $2,522,146
(including non-cash expenses $759,681) for fiscal year 2006. This increase
resulted from: an increase in gross profit of $345,688 or 191.7%; an
increase in operating expenses of $186,023 or 7.5%; an increase in interest
expenses of $534,852 or 231.0%; and changes in minority interest in a
subsidiary.

Review of Fourth Quarter

Revenues for the fourth quarter of 2007 were $2,915,067 an increase of
84.9% compared to $2,368,808 in the fourth quarter of 2006.

The net loss decreased to $763,199 for the three-month period ended
December 31, 2007 compared to $959,960 for the three months ended December
31, 2006.

Please refer to documents filed today with the Securities and Exchange
Commission for additional information on the results for the fourth quarter
and full year 2007.

Mr. Wei Li, Chairman and CEO of Kiwa, stated, ‘’We are pleased with the
growth in 2007 of the bio-feed business and look forward to continued
growth and improved margins in 2008 in this segment. We are also confident
that the bio-fertilizer business will prosper due to the accomplishments of
our team in 2007 and early 2008. Kiwa has previously announced:

—The newly finished first stage upgrade in Kiwa Shandong has
significantly strengthened our capability in manufacturing bio-
fertilizer products; and our marketing campaigns during past years
raised awareness of Kiwa among customers.
—At the end of the fourth quarter over 900 fertilizer selling terminals
had been established to sell Kiwa fertilizer products. These networks
of sales terminals provide excellent direct distribution of Kiwa’s
Green Food Association approved products within 4 areas in the south of
Hebei.
—For the future, Kiwa is actively negotiating to expand the sales
network to Neimeng, Jilin, Heilongjiang and Suzhou.  Mr. Wei Li also noted progress in the due diligence related to the
Letter of Intent with Shijiazhuang Huaxing Animal Medicine Co., Ltd.
("Huaxing") signed in December 2007. Along with the acquisition of the
factory that veterinary produces pharmaceuticals capable of manufacturing
AF-01 antiviral for avian flu, Kiwa’s objective is to offer three main
divisions of agricultural products.

Kiwa Bio-Tech 1st Quarter Revenues Increase 57.8% - $2.18 Million



Anticipates Significant Improvement During Spring Planting Season

BEIJING and CLAREMONT, Calif., May 9 /Xinhua-PRNewswire-FirstCall/ --
Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT)
announced revenues for the first quarter of 2008 ended March 31 were
$2,184,271, an increase of 57.8% above revenues of $1,384,093 for the first
quarter of 2007.

The significant revenue improvement is due to the expansion in Kiwa’s
bio-fertilizer and bio-enhanced feed businesses. During the first quarter
of 2008, revenue generated from the bio-fertilizer business increased
1136.7% to $148,104 from $11,976. Net sales contributed by the bio-enhanced
feed business increased 48.4%, to $2,036,167 from $1,372,117 in the first
quarter of the previous year.

The net loss increased to $686,195 for the three-month period ended
March 31, 2008 compared to $639,259 for the three months ended March 31,
2007. This net loss increase was partially the result of a decrease in
gross profit in the bio-feed business due to a sharp increase in prices of
raw materials and an increase in interest expenses partly offset by a
decrease in operating expenses. Please refer to documents filed today with
the Securities and Exchange Commission for additional information on the
results for the first quarter of 2008.

Mr. Wei Li, Chairman and CEO of Kiwa, stated, “Poor winter weather in
some planting areas of China and world wide increases in food prices
suggest that orders for the bio-fertilizer business will be strong during
the Spring planting season. We are pleased that our products are receiving
recognition by farmers and governmental agencies. For instance, in March,
the Ministry of Agriculture of the PRC granted an initial fertilizer
registration certificate to our wholly owned subsidiary, Kiwa Bio-Tech
Products (Shandong) Co., Ltd. for a newly developed bio-fertilizer product,
“Fudikang”. Fudikang is an inoculant that speeds decomposition of organic
matter. It was developed by Kiwa-CAU R&D;Centre which was established by
Kiwa and China Agricultural University, one of the most respected Chinese
universities in the field of agriculture. Kiwa is partaking in a 2008
initiative organized by the Chinese government: ‘The National Soil Organic
Matter Advancement Pilot Subsidy Project’.”

Mr. Wei Li also noted progress is being made related to the joint
venture with Shijiazhuang Huaxing Animal Medicine Co., Ltd. ("Huaxing") and
the acquisition of the factory that produces veterinary pharmaceuticals and
is capable of manufacturing AF-01 antiviral for avian flu. A press release
related to the joint venture and capital raised specifically for the joint
venture is expected shortly.

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative,
cost-effective, and environmentally safe bio-technological products for
agricultural and natural resources and environmental conservation. The
Company’s products are designed to enhance the quality of human life by
increasing the value, quality and productivity of crops and decreasing the
negative environmental impact of chemicals and other wastes. For more
information about the Company, please review documents filed with the SEC
(http://www.sec.gov) or visit the Company’s website at
http://www.kiwabiotech.com .

This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Any such
forward-looking statements involve risk and uncertainties that could cause
actual results to differ materially from any future results described by
the forward-looking statements. Risk factors that could contribute to such
differences include those matters more fully disclosed in the Company’s
reports filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the Company’s
estimates as of the date of the press release, and subsequent events and
developments may cause the Company’s estimates to change. The Company
specifically disclaims any obligation to update the forward- looking
information in the future. Therefore, this forward-looking information
should not be relied upon as representing the Company’s estimates of its
future financial performance as of any date subsequent to the date of this
press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation
Yvonne Wang
Tel:  +1-626-715-5855
Email:

Robert Schechter
Equity Communications
Tel:  +1-212-499-6809
Email:

SOURCE Kiwa Bio-Tech Products Group Corporation

Kiwa Bio-Tech Confirms Joint Venture Agreement With Shijiazhuang Huaxing Animal Medicine Co., Ltd.



BEIJING and CLAREMONT, Calif., May 13 /Xinhua-PRNewswire-FirstCall/ --
Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT)
announced finalization of an agreement establishing a joint venture company
capable of producing Kiwa’s AF-01 anti-viral product.

On May 9, General Manager of Shijiazhuang Huaxing Animal Medicine Co.,
Ltd. (’’Huaxing’’), Mr. Ruijun Li and his associates visited Kiwa’s
headquarters in Beijing for the final round of negotiations toward setting
up a proposed joint-venture. Both parties had extensively negotiated on the
terms of the joint-venture contract and finally confirmed all terms of the
contract.

The signing ceremony will be held next week, after the company name is
approved by the local Administration of Industry and Commerce.

ABOUT AF-01 ANTI-VIRAL FEED ENHANCEMENT AND AEROSOL

In May 2006, Kiwa acquired AF-01 Anti-viral Aerosol technology for
veterinary medicine applications including the exclusive production right
and other related rights to produce an anti-viral aerosol drug for use with
animals from Jinan Kelongboao Bio-Tech Co., Ltd. ("JKB"), which is
affiliated with Chinese Academy of Medical Sciences. The AF-01 aerosol
technology is a broad-spectrum anti-viral agent with potent inhibitory
and/or viricidal effects on a variety of RNA viruses found in animals and
fowls such as bird flu. Kiwa’s hope is to develop a commercialized product
in the form of a spray for applying in fowl houses and other animal holding
facilities to prevent and cure virus-caused diseases.

ABOUT SHIJIAZHUANG HUAXING ANIMAL MEDICINE CO., LTD.

Huaxing was founded in 1996. Huaxing is supported by animal husbandry
and veterinary medicine agencies at both provincial and municipal levels.
Huaxing has focused on building strong co-operative relationships with
academic institutions such as the Agricultural University of Heibei and
Hebei University of Science & Technology. Huaxing has developed: 12-series
of animal medicines and disinfectants, over 200 products for flocks and
herds, pigs, furry animals and pets. Huaxing holds 82 approval document
numbers for veterinary drug products. Huaxing was inspected by the Ministry
of Agriculture of the People’s Republic of China (’’Ministry of
Agriculture’’) and was awarded the GMP qualification in January 2005.
Huaxing’s distribution channel covers all of China with exception of Taiwan
and Tibet. Huaxing has become a modern high-tech veterinary drug enterprise
recognized as a strong force in R&D;, manufacturing and also distribution.

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative,
cost-effective, and environmentally safe bio-technological products for
agricultural and natural resources and environmental conservation. The
Company’s products are designed to enhance the quality of human life by
increasing the value, quality and productivity of crops and decreasing the
negative environmental impact of chemicals and other wastes. For more
information about the Company, please review documents filed with the SEC
(http://www.sec.gov) or visit the Company’s website at http://www.kiwabiotech.com
.

This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Any such
forward-looking statements involve risk and uncertainties that could cause
actual results to differ materially from any future results described by
the forward-looking statements. Risk factors that could contribute to such
differences include those matters more fully disclosed in the Company’s
reports filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the Company’s
estimates as of the date of the press release, and subsequent events and
developments may cause the Company’s estimates to change. The Company
specifically disclaims any obligation to update the forward- looking
information in the future. Therefore, this forward-looking information
should not be relied upon as representing the Company’s estimates of its
future financial performance as of any date subsequent to the date of this
press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation
Yvonne Wang
Tel:  +1-626-715-5855
Email:

Robert Schechter
Equity Communications
Tel:  +1-212-499-6809
Email:

SOURCE Kiwa Bio-Tech Products Group Corporation

Kiwa Bio-Tech Joint Venture to Produce Preventative for Avian Flu



Kiwa Bio-Tech & Hebei Huaxing Pharmaceuticals Co., Ltd form Hebei Kiwa
Huaxing Bio-Pharmaceuticals Co., Ltd.

BEIJING and CLAREMONT, Calif., May 27 /Xinhua-PRNewswire-FirstCall/ --
Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT)
announced entry into a contract for a joint venture named Hebei Kiwa
Huaxing Bio-Pharmaceuticals Co., Ltd. The joint venture company aims at
developing and producing Kiwa’s AF-01 anti-viral preventative for avian
flu. Kiwa Bio-Tech and Hebei Huaxing Pharmaceuticals Co., Ltd.
(’’Huaxing’’) held a ceremony recognizing their cooperation on May 22,
2008.

Under the terms of the contract, Kiwa Bio-Tech owns 70% of the equity
of the joint venture and Huaxing owns 30%. For more details about the
contract, please refer to 8-K filed with the SEC.

Mr. Ruijun Li, General Manager of Huaxing, noted, ‘’The combination of
our companies’ marketing network, technology, manufacturing expertise is
expected to support the growth of the joint venture.’’

Mr. Wei Li, Chairman and CEO of Kiwa, stated, ‘’we are pleased that
Kiwa will now be able to aggressively pursue commercial development of
AF-01 and veterinary pharmaceuticals as the third segment of its business.
Now along with continued growth of bio-feed and rapid expansion of
bio-fertilizers, Kiwa will be able to manufacture and market AF-01
Anti-viral Aerosol.’’

ABOUT AF-01 ANTI-VIRAL AEROSOL

In May 2006 Kiwa acquired AF-01 Anti-viral Aerosol technology for
veterinary medicine applications including the exclusive production right
and other related rights to produce an anti-viral aerosol drug for use with
animals from Jinan Kelongboao Bio-Tech Co., Ltd. ("JKB"), which is
affiliated with Chinese Academy of Medical Sciences. The AF-01 aerosol
technology is a broad-spectrum anti-viral agent with potent inhibitory
and/or viricidal effects on a variety of RNA viruses found in animals and
fowls such as bird flu. Kiwa’s hope is to develop a commercialized product
in the form of a spray for applying in fowl houses and other animal holding
facilities to prevent and cure virus-caused diseases, for example, avian
flu and foot-and-mouth disease.

ABOUT HUAXING

Huaxing was founded in 1996. Huaxing is supported by animal husbandry
and veterinary medicine agencies at both provincial and municipal levels.
Huaxing has focused on building strong co-operative relationships with
academic institutions such as the Agricultural University of Heibei and
Hebei University of Science & Technology. Huaxing has developed: 12-series
of animal medicines and disinfectants, over 200 products for flocks and
herds, pigs, furry animals and pets. Huaxing holds 61 approval document
numbers for veterinary drug products. Huaxing was inspected by the Ministry
of Agriculture of the People’s Republic of China (’’Ministry of
Agriculture’’) and was awarded the GMP qualification in January 2005.
Huaxing’s distribution channel covers all of China with exception of Taiwan
and Tibet. Huaxing has become a modern high-tech veterinary drug enterprise
recognized as a strong force in R&D;, manufacturing and also distribution.

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative,
cost-effective, and environmentally safe bio-technological products for
agricultural and natural resources and environmental conservation. The
Company’s products are designed to enhance the quality of human life by
increasing the value, quality and productivity of crops and decreasing the
negative environmental impact of chemicals and other wastes. For more
information about the Company, please review documents filed with the SEC
(http://www.sec.gov) or visit the Company’s website at http://www.kiwabiotech.com
.

This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Any such
forward-looking statements involve risk and uncertainties that could cause
actual results to differ materially from any future results described by
the forward-looking statements. Risk factors that could contribute to such
differences include those matters more fully disclosed in the Company’s
reports filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the Company’s
estimates as of the date of the press release, and subsequent events and
developments may cause the Company’s estimates to change. The Company
specifically disclaims any obligation to update the forward- looking
information in the future. Therefore, this forward-looking information
should not be relied upon as representing the Company’s estimates of its
future financial performance as of any date subsequent to the date of this
press release.

For more information, please contact:

Kiwa Bio-Tech Products Group Corporation
Yvonne Wang
Tel:  +1-626-715-5855
Email:

Robert Schechter
Equity Communications
Tel:  +1-212-499-6809
Email:

SOURCE Kiwa Bio-Tech Products Group Corporation

--------------------------------------------------------------------------------

Kiwa Bio-Tech Signs RMB 150 Million (US$21+ million) Fertilizer Contract



BEIJING and CLAREMONT, Calif., July 28 /Xinhua-PRNewswire-FirstCall/ --
Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT)
announces that Kiwa Bio-Tech Products (Shandong) Co., Ltd. (Kiwa Shandong)
signed fertilizer sales contracts totaling RMB 150 million (over US$21
million) with Jilin Tianma Science & Technology of Agriculture Co., Ltd.
and other distributors. Delivery of products under these contracts will be
carried out from August 2008 through March 2009.

Prior to entering into these Agreements, Kiwa Shandong has received
approval from the Ministry of Commerce of PRC for wholesaling other
companies’ fertilizer products; updated its business registration; and
filed for exemption from VAT, under applicable Chinese laws and
regulations. The Company has also entered into purchase contracts with
Jiangsu Zhongdong Group for relevant fertilizer products.

Kiwa Shandong has recently adjusted its product mix in cooperation with
Jiangsu Zhongdong Fertilizer Group with a focus on developing new compound
bio-fertilizers. Kiwa Shandong is also continuing to develop new organic
fertilizers to meet customer demand and is expected to introduce new
bio-fertilizer products for sale in the Chinese fertilizer markets by the
end of 2008. Starting in June 2008, Kiwa has been working closely with
Jiangsu Zhongdong Group Co., Ltd. ("Zhongdong") to develop and market
products. This announcement reflects contracts signed as part of previously
announced sales expectations of US$10,000,000 in the next six months.

Mr. Wei Li, CEO and Chairman of the Company, stated, “We are pleased by
the number of new customers and very large contracts signed at the end of
June 2008. Delivery of these fertilizer products and recognition of
revenues will begin in and significantly raise revenues in the third
quarter. While second quarter revenues will be improved they will not
reflect the significant rapid growth we expect in the second half of 2008.”

Mr. Li added, “Importantly, these agreements will also promote
development of Kiwa’s bio-fertilizer distribution networks by building
strategic alliances with large traditional chemical fertilizer dealers. We
expect that distributing other companies’ fertilizer products will be a
driver of Kiwa’s sales revenue. The Company is now applying itself to
adjusting its product mix, developing compound fertilizers and other new
fertilizer products through cooperation with Jiangsu Zhongdong Group. It is
expected that before the end of 2008, part of the Agreements will be
executed with newly developed products.”

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative,
cost-effective, and environmentally safe bio-technological products for
agricultural and natural resources and environmental conservation. The
Company’s products are designed to enhance the quality of human life by
increasing the value, quality and productivity of crops and decreasing the
negative environmental impact of chemicals and other wastes. For more
information about the Company, please review documents filed with the SEC
(http://www.sec.gov) or visit the Company’s website at http://www.kiwabiotech.com
.

To see a English language video related to Kiwa’s AF-01 anti-viral
preventative for avian flu:
http://video.google.com/videosearch?q=bird+flu+kiwa&sitesearch;=# or
http://www.youtube.com/watch?v=WF_9TTX_fSA;
http://www.youtube.com/watch?v=XG0gl9okjic

This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Any such
forward-looking statements involve risk and uncertainties that could cause
actual results to differ materially from any future results described by
the forward-looking statements. Risk factors that could contribute to such
differences include those matters more fully disclosed in the Company’s
reports filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the Company’s
estimates as of the date of the press release, and subsequent events and
developments may cause the Company’s estimates to change. The Company
specifically disclaims any obligation to update the forward- looking
information in the future. Therefore, this forward-looking information
should not be relied upon as representing the Company’s estimates of its
future financial performance as of any date subsequent to the date of this
press release.

For more information, please contact:

Yvonne Wang
Kiwa Bio-Tech Products Group Corporation
Tel:  +1-626-715-5855
Email:

Robert Schechter
Equity Communications
Tel:  +1-212-499-6809
Email:

SOURCE Kiwa Bio-Tech Products Group Corporation

.....

Kiwa Bio-Tech Receives Nationally Recognized Organic Products Certification



BEIJING and CLAREMONT, Calif., Aug. 4 /Xinhua-PRNewswire-FirstCall/ --
Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: KWBT)
announces that Kiwa Bio-Tech Products (Shandong) Co., Ltd. (Kiwa Shandong)
has received an Organic Products Certificate from the China Organic Food
Certification Center (COFCC).

After a two-month period of examination, verification and appraisal of
Kiwa Shandong’s products, the China Organic Food Certification Center
issued an Organic Products Certificate to Kiwa Shandong on July 18. COFCC
is the specialized agency under the Chinese Ministry of Agriculture to
propel the development of organic agriculture and to be engaged in
authentication and management of organic food and the organic food
industry. Moreover, it is the first national organic food qualification
agency authorized and structured by the Certification and Accreditation
Administration of the Peoples Republic of China (Grant No.
CNCA-R-2002-100), and has acquired recognition by the China National
Accreditation Service for Conformity Assessment (Registration No. CNAS
C115-0).

Mr. Wei Li, Chairman and CEO of Kiwa, stated, “Kiwa Shandong is the
second fertilizer manufacturing enterprise in Shandong Province of China,
that has acquired Organic Products Certification. With this certification,
orders for our organic fertilizer products should increase, and boost Kiwa
Shandong’s sales volume.”

ABOUT KIWA BIO-TECH PRODUCTS GROUP CORPORATION

The Company develops, manufactures, distributes and markets innovative,
cost-effective, and environmentally safe bio-technological products for
agricultural and natural resources and environmental conservation. The
Company’s products are designed to enhance the quality of human life by
increasing the value, quality and productivity of crops and decreasing the
negative environmental impact of chemicals and other wastes. For more
information about the Company, please review documents filed with the SEC
(http://www.sec.gov) or visit the Company’s website at http://www.kiwaiotech.com .

To see an English language video related to Kiwa’s AF-01 anti-viral
preventative for avian flu:
http://video.google.com/videoplay?docid=-7160666649865130385 or
http://www.youtube.com/watch?v=WF_9TTX_fSA ;
http://www.youtube.com/watch?v=XG0gl9okjic

This press release contains information that constitutes
forward-looking statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Any such
forward-looking statements involve risk and uncertainties that could cause
actual results to differ materially from any future results described by
the forward-looking statements. Risk factors that could contribute to such
differences include those matters more fully disclosed in the Company’s
reports filed with the Securities and Exchange Commission. The
forward-looking information provided herein represents the Company’s
estimates as of the date of the press release, and subsequent events and
developments may cause the Company’s estimates to change. The Company
specifically disclaims any obligation to update the forward- looking
information in the future. Therefore, this forward-looking information
should not be relied upon as representing the Company’s estimates of its
future financial performance as of any date subsequent to the date of this
press release.

For more information, please contact:

Yvonne Wang
Kiwa Bio-Tech Products Group Corporation
Tel:  +1-626-715-5855
Email:

Robert Schechter
Equity Communications
Tel:  +1-212-499-6809
Email:

SOURCE Kiwa Bio-Tech Products Group Corporation